Navigation Links
EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
Date:10/12/2009

VIENNA, Austria, October 12 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has appointed Bhupinder Hundle, PhD, to the newly created position of Senior Vice President Marketing & Sales. Dr. Hundle will be responsible for the worldwide sales of EUCODIS Bioscience' products. In 2009 the Company has started bringing to market its own enzymes portfolio. The Company had previously established its technology and its enzyme development expertise in commercial collaborations with industry partners.

"We are excited about the wealth of experience that Bhupinder brings on board in establishing and leading an effective sales force", said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "At EUCODIS Bioscience Bhupinder will be responsible for building the sales structure that optimally serves our target industries in Europe, the US, and Asia."

"I am proud to join a biotechnology company like EUCODIS Bioscience, with its proven capabilities in developing and bringing industrial enzymes to the market", commented Dr. Bhupinder Hundle. "With its industry experience and its powerful technology, EUCODIS Bioscience has the potential to become a key enabler of white biotechnology applications, both in established industries and in future technologies such as the generation of fine chemicals from biomass."

Dr. Hundle comes to EUCODIS Bioscience from Lonza, Switzerland, where he headed the sales team for the Lonza Cell Discovery product range in UK, Ireland, the Netherlands, and Northern Europe. Prior to joining Lonza Bhupinder served as European Sales Director for Amaxa AG for 6 years. He has more than 10 years of experience in working with B2B customers in the pharmaceutical and biotechnology industries in Europe and the US.

Dr. Hundle has a B.Sc. (Hons) degree in Molecular Biology, an M.Sc. degree in Medicinal Chemistry from Loughborough University, UK, and received his PhD degree in Biochemistry from Simon Fraser University, British Columbia, Canada. He worked as a postdoctoral fellow at Chemical Biodynamics Laboratory, Chemistry Department, University of California, Berkeley and as a Senior Research Fellow at University of California, San Francisco.

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visit http://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:
    Rudy Pandjaitan, PhD
    CEO
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna
    AUSTRIA
    +43-1-8900804
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
    http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net

SOURCE EUCODIS Bioscience


'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
2. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
3. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
4. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
5. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
6. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
7. Neurocrine Biosciences Presents Elagolix Data
8. Chipscreen and HUYA Bioscience to Present Clinical Data on Novel HDAC Inhibitor at the 2009 ASCO Annual Meeting
9. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
10. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
11. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
Breaking Medicine News(10 mins):